Recent Quotes (30 days)

You have no recent quotes
chg | %

Actinogen Medical Ltd  

(Public, ASX:ACW)   Watch this stock  
Find more results for ASX: ACW
0.0550
0.0000 (0.00%)
Oct 23 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range     -
52 week 0.04 - 0.09
Open     -
Vol / Avg. 0.00/158,042.00
Mkt cap 34.11M
P/E     -
Div/yield     -
EPS -0.01
Shares 620.19M
Beta     -
Inst. own     -
Nov 30, 2017
Actinogen Medical Ltd Annual Shareholders Meeting (Estimated) - 11:00AM GMT+11 - Add to calendar
  

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin -1767.42% -2048.11%
Operating margin -1761.92% -2042.63%
EBITD margin - -1811.12%
Return on average assets -25.33% -27.55%
Return on average equity -27.20% -29.69%
CDP Score - -

Address

Level 9, Suite 1, 68 Pitt Street
SYDNEY, NSW 2000
Australia
+61-2-89647401 (Phone)
+61-2-89647588 (Fax)

Website links

Description

Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.

Officers and directors

Geoffrey E.D. Brooke M.D. Chairman of the Board
Age: 60
John William Ketelbey Chief Executive Officer, Managing Director, Director
Peter Webse Company Secretary